CN101663263A - 包含(-)-o-去甲基文拉法辛的固体形式及其用途 - Google Patents

包含(-)-o-去甲基文拉法辛的固体形式及其用途 Download PDF

Info

Publication number
CN101663263A
CN101663263A CN200880012483A CN200880012483A CN101663263A CN 101663263 A CN101663263 A CN 101663263A CN 200880012483 A CN200880012483 A CN 200880012483A CN 200880012483 A CN200880012483 A CN 200880012483A CN 101663263 A CN101663263 A CN 101663263A
Authority
CN
China
Prior art keywords
odv
type
hydrochloride
crystalline form
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880012483A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·西泽恩斯基
哈罗德·S·威尔金森
约翰·史努尼安
诺曼·吉姆
莎伦·M·劳克林
罗杰·P·巴卡乐
凯文·普伦凯特
帕特里克·莫索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of CN101663263A publication Critical patent/CN101663263A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN200880012483A 2007-02-21 2008-02-21 包含(-)-o-去甲基文拉法辛的固体形式及其用途 Pending CN101663263A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90295007P 2007-02-21 2007-02-21
US60/902,950 2007-02-21

Publications (1)

Publication Number Publication Date
CN101663263A true CN101663263A (zh) 2010-03-03

Family

ID=39432564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880012483A Pending CN101663263A (zh) 2007-02-21 2008-02-21 包含(-)-o-去甲基文拉法辛的固体形式及其用途

Country Status (18)

Country Link
US (2) US20090005457A1 (enExample)
EP (2) EP2114863B1 (enExample)
JP (1) JP5666140B2 (enExample)
KR (1) KR101528326B1 (enExample)
CN (1) CN101663263A (enExample)
AR (1) AR065431A1 (enExample)
AU (1) AU2008218997B2 (enExample)
BR (1) BRPI0807604A2 (enExample)
CA (1) CA2678599C (enExample)
ES (1) ES2609264T3 (enExample)
IL (1) IL200514A (enExample)
MX (1) MX2009008705A (enExample)
NZ (2) NZ599480A (enExample)
RU (1) RU2477269C2 (enExample)
SG (1) SG175611A1 (enExample)
TW (1) TWI446903B (enExample)
WO (1) WO2008103461A2 (enExample)
ZA (1) ZA200905698B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103772220A (zh) * 2013-12-03 2014-05-07 镇江圣安医药有限公司 1-[2-二甲基氨基-1-（4-甲氧基苯基）乙基]环己醇的新型衍生物及其应用
CN105348119A (zh) * 2015-11-04 2016-02-24 连云港宏创药业有限公司 晶状的文拉法辛代谢物及其制备方法
CN109771380A (zh) * 2017-11-10 2019-05-21 连云港恒运药业有限公司 去甲文拉法辛盐酸盐药物组合物及其制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2683697C (en) * 2007-04-09 2016-08-16 Sepracor Inc. Methods and compositions for treating sleep-related breathing disorders
CZ2008756A3 (cs) * 2008-11-27 2010-03-24 Zentiva, A. S. Zpusob prípravy desvenlafaxinu a jeho solí
CZ302145B6 (cs) * 2009-07-15 2010-11-10 Zentiva, K. S. Zpusob prípravy desvenlafaxinu a jeho solí
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
CA2773948A1 (en) * 2011-04-12 2012-10-12 Geo. Pfau's Sons Company, Inc. Method for rendering animal materials
JP6751200B2 (ja) * 2017-02-09 2020-09-02 アール エル ファインケム プライベート リミテッド １−［２−（ジメチルアミノ）−１−（４−ヒドロキシフェニル）エチル］−シクロヘキサノール及びその塩の製造方法
US12227566B2 (en) 2018-12-05 2025-02-18 Hedgehog, Inc. Endothelin receptor type a activity regulating antibody
CA3178094A1 (en) * 2020-05-26 2021-12-02 Olaf SCHLACHTER Process for preparing pet food and pet food obtainable thereby
CN116199590B (zh) * 2022-12-26 2024-12-24 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
WO2007005961A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5213738A (en) 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ATE369330T1 (de) 2001-02-12 2007-08-15 Wyeth Corp O-desmethyl-venlafaxine succinat salz
WO2003050075A1 (en) * 2001-12-05 2003-06-19 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
RU2004139075A (ru) 2002-06-10 2005-06-27 Уайт (Us) Новые формиат 0-десметилвенлафаксина

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US20060199860A1 (en) * 1998-12-01 2006-09-07 Jerussi Thomas P Salts of (-)-O-desmethylvenlafaxine
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
WO2007005961A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103772220A (zh) * 2013-12-03 2014-05-07 镇江圣安医药有限公司 1-[2-二甲基氨基-1-（4-甲氧基苯基）乙基]环己醇的新型衍生物及其应用
CN105348119A (zh) * 2015-11-04 2016-02-24 连云港宏创药业有限公司 晶状的文拉法辛代谢物及其制备方法
CN105348119B (zh) * 2015-11-04 2017-09-15 江苏豪森药业集团有限公司 晶状的文拉法辛代谢物及其制备方法
CN109771380A (zh) * 2017-11-10 2019-05-21 连云港恒运药业有限公司 去甲文拉法辛盐酸盐药物组合物及其制备方法

Also Published As

Publication number Publication date
KR101528326B1 (ko) 2015-06-11
EP2500337A3 (en) 2012-12-26
US20090005457A1 (en) 2009-01-01
MX2009008705A (es) 2009-09-10
TW200901955A (en) 2009-01-16
US20160355457A1 (en) 2016-12-08
ES2609264T3 (es) 2017-04-19
RU2477269C2 (ru) 2013-03-10
ZA200905698B (en) 2010-10-27
NZ599480A (en) 2013-10-25
CA2678599C (en) 2015-11-10
AU2008218997B2 (en) 2013-06-20
WO2008103461A3 (en) 2008-11-13
SG175611A1 (en) 2011-11-28
NZ579137A (en) 2012-05-25
WO2008103461A2 (en) 2008-08-28
BRPI0807604A2 (pt) 2014-07-22
AU2008218997A1 (en) 2008-08-28
AR065431A1 (es) 2009-06-10
CA2678599A1 (en) 2008-08-28
IL200514A (en) 2013-12-31
JP5666140B2 (ja) 2015-02-12
EP2114863B1 (en) 2016-10-05
RU2009135016A (ru) 2011-03-27
EP2114863A2 (en) 2009-11-11
KR20090113904A (ko) 2009-11-02
TWI446903B (zh) 2014-08-01
JP2010519300A (ja) 2010-06-03
EP2500337A2 (en) 2012-09-19
IL200514A0 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
CN101663263A (zh) 包含(-)-o-去甲基文拉法辛的固体形式及其用途
CZ20013607A3 (cs) Farmaceutický prostředek
JP6126040B2 (ja) ニコサミド（Ｎｉｃｏｕｓａｍｉｄｅ）化合物の五つの晶型、その製法やその薬物組合と用途
EP2185501B1 (en) Crystalline form of (r,r)-tramadol-(s)-naproxen salt for the treatment of pain
JP2015199763A (ja) トランスノルセルトラリンの製剤、塩、及び多形体、並びにその使用
US20100035994A1 (en) Novel hydrate form of o-desmethyl venlafaxine succinate
CN102770416B (zh) 美他沙酮共晶体
CN101460474A (zh) 作为钾通道开放剂的3,4-二氨基-3-环丁烯-1,2-二酮衍生物
HK1141271A (en) Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
JP2017519829A (ja) アルツハイマー病の処置用のｎ−［２−（６−フルオロ−１ｈ−インドール−３−イル）エチル］−３−（２，２，３，３−テトラフルオロプロポキシ）ベンジルアミン塩酸塩の新規な多形形態
WO2012142067A2 (en) Formulations, salts, and solid forms of substituted cyclohexylmethanamines, processes for preparation, and uses thereof
WO2009124458A1 (zh) 苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1141271

Country of ref document: HK

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Sepracor Inc.

Address before: Massachusetts, USA

Applicant before: Sepracor Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SEPRACOR INC. TO: SUNOVION PHARMACEUTICALS INC.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100303

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1141271

Country of ref document: HK